Skip to main content
SpringerLink
Log in

Disease Management Update

  • From the World Literature
  • Published:
Disease Management & Health Outcomes

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Pharmacoeconomics & Outcomes News provides comprehensive coverage of the biomedical literature on health economics and outcomes research, and summarizes information selected from more than 1600 journals. The use of tradenames, identified by [∼] or the use of a registered (®) or trademark (™) symbol, is for product identification purposes only and does not imply endorsement.

  2. * One of the researchers was affiliated with Merck.

  3. ** Costs (2005 Canadian dollars) were calculated from the perspective of the ministry of health, and included those associated with vaccine acquisition and administration, conventional cytology, colposcopy, biopsy, and treatment following CIN 2/3. All future costs and outcomes were discounted at a rate of 3% per annum.

  4. * Costs included those associated with wholesale drug acquisition, surgery, complications of parathyroidectomy, and death due to parathyroidectomy, and were calculated using 2005 US Centers for Medicare & Medicaid Services Average National Reimbursement figures.

  5. * This study was supported by Janssen-Cilag.

  6. * The statutory health insurance perspective considered direct medical costs (practitioner fees, oral glucose tolerance tests, outpatient visits, and diabetes educator sessions). The societal perspective considered direct medical costs, nondirect medical costs (educational fees and patient exercise time), and indirect costs (patient consultation time and healthcare professional educational time).

  7. * Costs were those associated with the intervention, such as training and delivery costs, and the usual costs of NHS treatment (pharmaceuticals, and GP and hospital visits).

  8. * The costs (€; 2004 values), including the direct and indirect costs associated with illness, were discounted at 4% per annum. The analysis also included estimates of the beneficial effects for unvaccinated individuals (herd protection).

  9. * The cost analysis from the provider perspective included only direct costs (medical visits, antibacterial consumption, antipyretic consumption, and hospitalization in a pediatric hospital) and benefits. From the societal perspective the analysis included direct and indirect costs and benefits.

  10. * 2006 values.

  11. * Physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health.

  12. ** General health, physical function, role function, social function, pain, energy/fatigue, health distress, quality of life, and health transition.

References

  1. Clark RA, Inglis SC, McAlister FA, et al. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and metaanalysis. BMJ 2007 May 5; 334(7600): 942.

    Article  PubMed  Google Scholar 

  2. Grancelli HO, Ferrante DC. Telephone interventions for disease management in heart failure: such support for patients at home cuts admissions to hospital for heart failure. BMJ 2007; 334: 910–1

    Article  PubMed  Google Scholar 

Reference

Reference

  • Brisson M, Van de Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007 Jul 20; 25(29): 5399–408

    Article  PubMed  Google Scholar 

Reference

  • Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007; 49(6): 801–13

    Article  PubMed  Google Scholar 

Reference

  • Reinhardt UE. Faith based health policy: the urge to privatise [abstract]. BMJ 2007 Jun 9; 334(7605): 1193

    Article  PubMed  Google Scholar 

Reference

  • Welty TE. Pharmacy and generic substitution of antiepilpetic drugs: missing in action? Ann Pharmacother 2007 Jun 6; 41(6): 1065–8

    Article  PubMed  Google Scholar 

Reference

  • Williams J, Klinepeter K, Palmes G, et al. Behavioral health practices in the midst of black box warnings and mental health reform. Clin Pediatr 2007; 46(5): 424–30

    Article  Google Scholar 

Reference

  • Berliner MN, Giesecke T, Bornhövd KD. Impact of transdermal fentanyl on quality of life in rheumatoid arthritis. Clin J Pain 2007 Jul–Aug; 23(6): 530–4

    Article  PubMed  Google Scholar 

Reference

  • Icks A, Rathmann W, Haastert B, et al. Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a real world routine healthcare setting: model based on the KORA Survey 2000. Diabet Med 2007 May; 24(5): 473–80

    Article  PubMed  CAS  Google Scholar 

Reference

  • Scott A, Tinelli M, Bond C. Costs of a community pharmacist-led medicines management service for patients with coronary heart disease in England: healthcare system and patient perspectives. Pharmacoeconomics 2007; 25(5): 397–411

    Article  PubMed  Google Scholar 

Reference

  • Hubben GAA, Bos JM, Glynn DM, et al. Enhanced decision support for policy makers using a web interface to health-economic models — illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine 2007 May 4; 25(18): 3669–78

    Article  PubMed  CAS  Google Scholar 

Reference

  • Navas E, Salleras L, Domínguez A, et al. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3–14 years from the provider and societal perspectives. Vaccine 2007 Apr 20; 25(16): 3233–9

    Article  PubMed  CAS  Google Scholar 

Reference

  • Black PC, Basen-Engquist K, Wang X, et al. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. BJU Int 2007 Jul; 100(1): 63–9

    Article  PubMed  CAS  Google Scholar 

Reference

  • Diamond GA, Kaul S, Shah PK, et al. Screen testing: cardiovascular prevention in asymptomatic diabetic patients. J Am Coll Cardiol 2007 May 15; 49(19): 1915–7

    Article  PubMed  Google Scholar 

Reference

  • Siddiqui U, Bini EJ, Chandarana K, et al. Prevalence and impact of diarrhea on healthrelated quality of life in HIV-infected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol 2007 May–Jun; 41(5): 484–90

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Disease Management Update. Dis-Manage-Health-Outcomes 15, 257–262 (2007). https://doi.org/10.2165/00115677-200715040-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200715040-00007

Keywords

Search

Navigation